NYSE · CRL

Charles River Laboratories International, Inc.

Healthcare · Medical - Diagnostics & Research

$281.67▲ 3.02% ($8.26)at close

After hours$280.00▼ 0.59%8:00 PM ET

52-week

$144.26$303.31

No multiple

What the market price implies · Reverse DCF

To support a price of $281.67, this model requires revenue to grow by 20.21%/yr over the next 10 years, compounded annually.

Historical revenue grew by 3.2%/yr over the past 4 years. The required annual growth rate is 17.01 percentage points higher.

Selected forecast · Base scenario

0.8%/yr · actual 10-year annualized revenue growth

Year 1 growth: 0%

Market-implied · Base operating assumptions + edited margins

20.21%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$281.67

Estimated value / share

$34.74

Base scenario

This estimate is 87.67% below the price used.

USD · TTM ending 2026-06-27

Year 1 growth 0% · Ending margin 12.35% · Discount rate 11.13%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 17, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-27
Data refreshed: Sep 17, 2026, 7:46 PM UTC · cache

Why this method?

FCFF is positive, but the series is too unstable to anchor a direct cash-flow CAGR and the business still fails the steady-state comparability checks. Use a revenue-and-margin transition model instead of normalizing and compounding current FCFF.

Is FCFF positive and has it been for 3+ consecutive years? 15 consecutive positive FCFF years are available.

Is FCFF stable (not swinging >30% year to year)? The largest recent FCFF swing is 274.2%.

Do you have 5+ years of positive FCFF history? 15 consecutive positive FCFF years are available.

Is the business model structurally similar to what it should be in 10 years? Operating margin moved 11.0 percentage points across the last five years, above the 10.0-point stability threshold, so steady-state FCFF is not a reliable anchor yet.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 84.61%Revenue (TTM): -0.74%FCF (TTM): -35.94%P/FCF: 88th pct

What changed

The stock rose 84.61% over the last year. Revenue declined 0.74% over the trailing twelve months. Operating margin moved from 3.09% to 12.35%. Free cash flow declined 35.94% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at 12.35%. A decisive move in revenue — currently down 0.74% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries.

CEOBirgit Girshick

SectorHealthcare

IndustryMedical - Diagnostics & Research

Employees19,000

IPO dateJun 23, 2000

https://www.criver.com

Market multiples

Forward P/E—

EV/EBITDA31.51

Enterprise value$12.95B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth-2.72%

Gross margin (FY2025)30.52%▼2.4ppvs FY2024

Operating margin (FY2025)12.65%▲7.0ppvs FY2024

ROE-7.7%▼3.3ppvs FY2025

Analyst consensus

RatingBuy

Target price$282.36▲0.24%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 4, 2026

Q4 FY26 · EPS est $2.96 · Revenue est $958.47M

View